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Aim: Selective chemogenetic modulation of locus coeruleus (LC) neurons would allow
dedicated investigation of the role of the LC-NA pathway in brain excitability and
disorders such as epilepsy. This study investigated the feasibility of an experimental
set-up where chemogenetic modification of the brainstem locus coeruleus NA neurons
is aimed at and followed by LC unit activity recording in response to clozapine.
Methods: The LC of male Sprague-Dawley rats was injected with 10 nl of adeno-
associated viral vector AAV2/7-PRSx8-hM3Dq-mCherry (n = 19, DREADD group) or
AAV2/7-PRSx8-eGFP (n = 13, Controls). Three weeks later, LC unit recordings were
performed in anesthetized rats. We investigated whether clozapine, a drug known to
bind to modified neurons expressing hM3Dq receptors, was able to increase the LC
firing rate. Baseline unit activity was recorded followed by subsequent administration
of 0.01 and 0.1 mg/kg of clozapine in all rats. hM3Dq-mcherry expression levels
were investigated using immunofluorescence staining of brainstem slices at the end
of the experiment.
Results: Unit recordings could be performed in 12 rats and in a total of 12 neurons
(DREADDs: n = 7, controls: n = 5). Clozapine 0.01 mg/kg did not affect the mean firing
rate of recorded LC-neurons; 0.1 mg/kg induced an increased firing rate, irrespective
whether neurons were recorded from DREADD or control rats (p = 0.006). Co-labeling
of LC neurons and mCherry-tag showed that 20.6 ± 2.3% LC neurons expressed the
hM3Dq receptor. Aspecific expression of hM3Dq-mCherry was also observed in non-LC
neurons (26.0 ± 4.1%).
Conclusion: LC unit recording is feasible in an experimental set-up following
manipulations for DREADD induction. A relatively low transduction efficiency of the used
AAV was found. In view of this finding, the effect of injected clozapine on LC-NA could
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not be investigated as a reliable outcome parameter for activation of chemogenetically
modified LC neurons. The use of AAV2/7, a vector previously applied successfully to
target dopaminergic neurons in the substantia nigra, leads to insufficient chemogenetic
modification of the LC compared to transduction with AAV2/9.
Keywords: locus coeruleus, chemogenetics, designer receptor exclusively activated by designer drugs, unit
recording, clozapine, vagus nerve stimulation
INTRODUCTION
The Locus coeruleus (LC)-noradrenaline (NA) pathway is
believed to play an important role in the development and
treatment of epilepsy (Giorgi et al., 2004). Different preclinical
studies demonstrated the anti-epileptic role of endogenous NA
since lesioning LC accelerates the rate of amygdala kindling
(Giorgi et al., 2004) and attenuates seizure-suppressing effects
of Vagus Nerve Stimulation (VNS) (Krahl et al., 1998). In
general, it is known that the LC-NA pathway modulates brain
excitability which is evident based on hippocampal evoked
potentials (EP) and electro-encephalography (EEG). Activation
of the LC-NA system induces synaptic plasticity in the form
of long term depression or long term potentiation depending
on simultaneous activation of the neural target and glutamate
release. These paradoxal effects could be explained by the “hot
spot theory” referring to the hypothesis that the local increase
in NA concentration is depending on the initial activation of
the neural target, where local glutamate increases lead to NA
increase of LC-varicosities (Lacaille and Harley, 1985; Walling
et al., 2004; Brown, 2005; Reid and Harley, 2010; Hansen and
Manahan-Vaughan, 2015; Mather et al., 2019).
To further unravel the precise role of the LC-NA pathway
in modulation of brain excitability and eventually even in
the mechanism of action of VNS, selective LC modulation is
desirable. Chemogenetics is a technique able to modulate specific
brain structures with high cellular specificity using Designer
Receptors Exclusively Activated by Designer Drugs (DREADD).
DREADDs are muscarinic metabotropic receptors (hM3Dq for
excitation, hM4Di for inhibition) that are genetically engineered
to be inert for the endogenous ligand acetylcholine but are known
to respond to so called “designer drugs” such as Clozapine-N-
Oxide (CNO) (Gomez et al., 2017). CNO is a major metabolite
of clozapine, a clinically used antipsychotic drug. Activation of
Gq-coupled hM3Dq by CNO was previously shown to activate
neurons through phospholipase C (PLC) dependent mechanisms
(Alexander et al., 2009). Activation of hM3Dq-NA neurons
under isoflurane anesthesia by systemic CNO administration was
demonstrated to enhance recovery of arousal from anesthesia by
Aston-Jones et al. (Vazey and Aston-Jones, 2014).
Frequently used techniques for in vivo transduction of LC
neurons consists of an intracerebral injection of a viral vector,
such as adeno-associated viral vector (AAV) or canine adeno-
associated viral vector (CAV), in the vicinity of LC. To achieve
LC specific expression of the DREADD a selective promotor is
used such as PRSx8, a synthetic dopamine-β-hydroxylase (DBH)
promotor (Hwang et al., 2001; Vazey and Aston-Jones, 2014).
Alternatively site-specific recombinase technology can be used
which consists of injecting a Cre-dependent AAV vector in
TH-Cre transgenic mice. Previous research groups using AAVs
mostly used an AAV2/9 which resulted in successful transduction
of LC (Vazey and Aston-Jones, 2014; Fortress et al., 2015;
Kane et al., 2017; Rorabaugh et al., 2017; Cope et al., 2019;
Zerbi et al., 2019).
In this study we examined the feasibility of injecting AAV2/7,
carrying the PRSx8-hM3Dq-mCherry construct, to induce LC-
specific expression of the excitatory hM3Dq DREADD. To
achieve this an AAV2/7 was injected in the rat LC. This AAV
serotype was used because it has proven efficiency in transducing
high numbers of dopaminergic neurons in the substantia nigra
(Van der Perren et al., 2011).
We also aimed to determine the effects of systemic
administration of two different subclinical doses of clozapine
(0.01 and 0.1 mg/kg). Earlier evidence showed that CNO,
upon systemic injection in rats, is back-converted to clozapine
(MacLaren et al., 2016). In contrast to CNO, clozapine easily
crosses the blood-brain barrier. Since clozapine has high affinity
for DREADDs, activation of DREADDs in the brain by systemic
CNO is mainly caused by its metabolite clozapine (Gomez
et al., 2017). Importantly, at therapeutic doses, i.e., 1–10 mg/kg,
clozapine binds to a broad range of neuroreceptors including
dopamine D2−4, serotonin 5-HT2A, 5-HT2C, muscarinic M1, M2,
M3, M4, adrenergic α1 and α2, as well as histamine H1 receptors
(Svensson et al., 1975). Some of these receptors are expressed
in LC (Egan and North, 1985; Szabo and Blier, 2001; Korotkova
et al., 2005; Bærentzen et al., 2019).
The aim of our study was to design an experimental
approach where selective modulation of neurons of the LC
through chemogenetic stimulation would allow to investigate the
noradrenergic pathway in the regulation of brain excitability.
The aim was to use the hM3DQ DREADD approach, systemic
administration of subclinical doses of clozapine and recording
of LC neuronal firing modulation with the ultimate aim of
performing this in awake epileptic rats in the future.
MATERIALS AND METHODS
Animals
Thirty-two adult male Sprague-Dawley rats (Envigo, The
Netherlands) were used in this study and treated according
to European guidelines (directive 2010/63/EU). The study
protocol was approved by the local Ethical Committee on
Animal Experiments of Ghent University (ECD 16/31). Animals
were kept under environmentally controlled conditions: 12 h
light/dark cycles with artificially dimmed light, temperature and
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relative humidity at 20–23◦C and 40–60%, respectively, with
food (Rats and Mice Maintenance, Carfil, Belgium) and water
ad libitum. All animals were housed individually in type III
H cages (Tecniplast, Australia) on wood-based bedding (Carfil,
Belgium). Cages were enriched with paper nesting material
(Nestil, Carfil, Belgium).
Viral Vector Administration
Animals (n = 32; 9–10 weeks old; 309 ± 15 g body weight)
were anesthetized with a mixture of medical oxygen and
isoflurane (5% for induction, 2% for maintenance, Isoflo,
Zoetis, United Kingdom); body temperature was controlled
using a heating pad. Rats were placed in a stereotaxic frame
(Stoelting, United States) and the skull was exposed. Bregma
was lowered 2 mm relative to lambda (15◦ head angle) to
target the LC and avoid the transverse sinus. Using a Neuro-
Syringe (Hamilton model 7001 point style 3, Hamilton company,
Nevada, United States) and Quintessential Stereotaxic Injection
system (flowrate 2 nl/min, Stoelting, United States), injections
of 10 nl of an adeno-associated viral vector (AAV) serotype
2/7 containing a PRSx8-hM3Dq-mCherry plasmid (5.99 × 1012
GC/ml) (n = 19; 11 unilateral and 8 bilateral) or AAV2/7-
PRSx8-eGFP plasmid as a control (n = 13; 5 unilateral and
8 bilateral) were performed in the LC (3.9 AP, 1.15 ML
relative to lambda, −5.7 DV from dura). After injection the
syringe was left in place for an additional 5 min and was then
slowly withdrawn to avoid backflow. Following surgery, animals
were subcutaneously (s.c.) injected with the non-steroidal anti-
inflammatory drug meloxicam (NSAID, 1 mg/kg metacam,
Boehringer Ingelheim, Germany) and lidocaine (5% Xylocaine
gel, AstraZeneca, United Kingdom) was applied to the incision
site to minimize discomfort. All animals recovered 3 weeks in
their home cage to allow for optimal viral vector expression
(Smith et al., 2016).
Electrophysiology: In vivo Extracellular
Unit Recording in Locus Coeruleus
Neurons
At least 3 weeks after viral vector injection animals (387 ± 26 g
body weight) were used for LC unit recordings. Rats were
anesthetized with a mixture of medical oxygen and isoflurane
(5% for induction, 1.5% for maintenance, n = 18) or were
induced with 5% isoflurane followed by an intraperitoneal
injection of urethane (1.5 g/kg, n = 14). Rats were placed
in the stereotaxic frame as described in section “Viral Vector
Administration.” For unit recording, a tungsten microelectrode
(0.008′′/200 µm shank diameter, impedance ≥1.5 M, FHC,
United States) was implanted under electrophysiological control
and audio monitoring to target LC neurons (Bouret et al.,
2003). As a reference and ground, two custom made epidural
scalp electrodes, consisting of an insulated copper wire attached
to a stainless steel microscrew (1.75 mm diameter; Plastics
One, United States) were placed above the left and right
frontal cortex. Electrophysiological recordings were amplified
(x10 000), filtered (300 Hz-3 kHz) and digitized at 31 kHz
using a 1401 micro and Spike2 software (Cambridge Electronic
Design, United Kingdom) for online visualization of action
potentials and storage for post-processing. Action potentials are
detected as input signals crossing a trigger level set by the
researcher. LC neurons can be visually identified online as they
are characterized by the occurrence of a typical pattern called
“a phasic burst inhibition” following a foot pinch (Vazey and
Aston-Jones, 2014; Hirschberg et al., 2017). After identification
of LC neurons, a stable baseline period of 300 s was recorded
followed by subsequent subcutaneous injections of clozapine into
the loose skin of the neck, starting with the lowest dose of
0.01 mg/kg and followed by 0.1 mg/kg (dissolved in 3% DMSO
in saline). Action potentials were recorded for at least 650 s after
each clozapine injection. After the recording period following
0.1 mg/kg clozapine administration, clonidine (0.04 mg/kg),
an α2 agonist which inhibits the spontaneous firing of LC-
NA neurons, was injected subcutaneously to confirm the LC
identity of recorded neurons (Svensson et al., 1975). Recording
was stopped when a decrease in the firing frequency at least to
baseline levels was observed.
Histology
At the end of the unit recording sessions, animals were
deeply anesthetized with an overdose of sodium pentobarbital
(200 mg/kg, i.p.) and transcardially perfused with phosphate-
buffered saline (PBS) followed by paraformaldehyde (4%, pH
7.4). The brains were post fixed in paraformaldehyde (4%, pH 7.4)
for 24 h and subsequently cryoprotected in a sucrose solution of
10–20–30% at 4◦C, snap-frozen in isopentane and stored in liquid
nitrogen at−196◦C. After 1 h on−20◦C, coronal cryosections of
40µm were made using a cryostat (Leica, Germany). The sections
were rinsed twice for 5 min in distilled water (dH2O) followed by
incubation in 0.5% and 1% H2O2 for 30 and 60 min, respectively,
to block endogenous peroxidase activity. After washing twice
for 5 min in PBS, sections were incubated in blocking buffer
(BB) made of PBS containing 0.4% Fish Skin Gelatin (FSG)
and 0.2% Triton X for 45 min to block non-specific antibody
binding sites. The sections were then incubated in primary
antibodies to visualize noradrenergic LC neurons and GFP or
mCherry tag, respectively, with mouse anti-DBH (1:1000, Merck,
clone 4F10.2) and chicken anti-green fluorescent protein (1:1000,
Abcam, ab13970) or rabbit anti-red fluorescent protein (targeting
mCherry, 1:1000, Rockland, ROCK600-901-379) diluted in BB
for 1 h at room temperature and subsequently overnight at 4◦C.
On the next day the sections were washed twice in blocking buffer
for 10 min followed by incubation in secondary antibodies Alexa
Fluor goat anti-mouse 488 nm (1:1000, Abcam, Ab 150113) or
Alexa Fluor goat anti-mouse 594 nm (1:1000, Abcam, ab150176)
against DBH+ cells and Alexa goat anti-rabbit 594 nm or Alexa
fluor goat-anti chicken 488 nm (against mCherry or GFP tag)
diluted in BB for 1 h at room temperature in darkness. After
washing twice in PBS for 5 min, a nuclear DAPI staining was
performed and subsequent rinsing in PBS (2 × 5 min). Sections
were mounted on glass slides and cover slipped using Vectashield
H1000 mounting medium (Vector Laboratories, United States) to
prevent photo bleaching.
The viral vector expression levels were determined using a
fluorescence microscope (Carl Zeiss, Axiovert 200M and Nikon
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Eclipse TE2000-E, Germany). Pictures of DAPI, DBH and GFP
or mCherry were taken with the AxioVision Microscope Software
(6D acquisition) connected to the Carl Zeiss fluorescence
microscope on the 10x magnification. For each animal that
underwent successful unit recording, images were taken from
three slices along the anterior-posterior axis of the LC and
exported as TIFF files before being analyzed in Fiji-ImageJ
software. To determine hM3Dq-DBH colocalization, three
sections containing LC per animal were used to quantify the
number of DBH+ LC cells by placing virtual markers on a merged
image of DBH+/DAPI. These markers were then copied on
the merged image of DBH+/mCherry to determine the number
of LC cells expressing hM3Dq-mCherry. To quantify aspecific
hM3Dq-mCherry expression, cells that were DBH−/mCherry+
were counted and divided by the total number of mCherry+ cells.
Electrophysiological Data Analysis
Units which responded with a typical phasic bursting/tonic
inhibition pattern after foot pinch, of which the activity could
be stably recorded upon the administration of both clozapine
dosages and whose activity was inhibited by administration
of clonidine were included in the analysis. Units were oﬄine
identified in Spike2 and confirmed as independent using
principal component and autocorrelation (Chaijale et al., 2013).
The mean firing frequency per 10 s bins was calculated for an
episode of 300 s during baseline (30 data points) and 300 s after
injection of both clozapine dosages (30 data points before the next
injection covering the maximum effect of each dose). DREADD
and control group averages of baseline and clozapine (0.01 and
0.1 mg/kg) epochs were calculated. To determine the effect of
group (DREADD vs. control), treatment (baseline, clozapine
0.01 mg/kg and clozapine 0.1 mg/kg) and their interaction a
two-way repeated measures ANOVA was performed, followed by
post hoc Bonferroni test for comparing individual conditions. All
data are presented as mean ± standard error of mean (SEM).
Statistical analysis was performed in SPSS for windows (version
25). Graphs were made in GraphPad Prism 6.
RESULTS
Effect of Systemic Clozapine
Administration on LC Firing Frequency
Successful electrophysiological recordings were performed in 12
animals. A total of 12 neurons were recorded, 7 in DREADD-
injected animals and 5 in control animals, all characterized by
foot pinch elicited phasic bursting and decreased firing frequency
after clonidine administration. A two-way repeated measures
ANOVA showed no interaction between treatment and group
(F = 0.212, p = 0.655). No significant effect of group was reported
(F = 1.429, p = 0.259) although treatment has a significant
effect on the firing frequency (F = 14.623, p = 0.003). Systemic
administration of the 0.01 mg/kg clozapine had no significant
effect on the mean firing frequency (2.72 ± 0.48 Hz, p = 0.468)
of recorded LC neurons compared to baseline (2.34 ± 0.30 Hz)
whereas an increased firing rate was observed after 0.1 mg/kg
clozapine (3.57 ± 0.54 Hz, p = 0.006), irrespective whether
recordings were performed in DREADD or control animals.
A significant difference between the two doses of clozapine
on the firing frequency was observed (p = 0.003) (Figure 1).
In all LC neurons, firing frequency was reduced to baseline
levels or completely inhibited after clonidine administration
confirming LC identity.
Viral Vector Expression
Double label immunostaining for the mCherry tag coupled to the
hM3Dq receptor and DBH was used to quantify the transduction
efficiency of the viral vector in LC-NA neurons and its specificity.
All animals that underwent successful unit recording at least
3 weeks after viral vector administration showed expression
of hM3Dq in LC-NA cells and adjacent axons although there
was variability in the fraction of LC cells expressing hM3Dq
(Figures 2A–C). HM3Dq expression was evident in 20.6 ± 2.3%
LC neurons (21 sections; three sections/animal; range 11–32%).
Aspecific expression of hM3Dq-mCherry was also observed in
cells outside the LC (26.0 ± 4.1% of mCherry positive cells was
DBH negative) (Figure 2B).
DISCUSSION
In this study we tested the feasibility of an experimental approach
where LC neurons were transduced with AAV vectors for
FIGURE 1 | The effect of systemic administration of different doses of
clozapine on the mean firing frequency of LC neurons in DREADD and control
injected animals. Electrophysiological recordings were performed in 12
animals (DREADD group n = 7; control n = 5), in each animal one neuron was
recorded for a stable baseline period (300 s) followed by subsequent
injections of clozapine (0.01 and 0.1 mg/kg, s.c.). No difference in the effect of
clozapine on the firing frequency of neurons recorded in DREADD-injected or
control animals was observed (F = 14.623, p = 0.003). The highest dose of
clozapine (0.1 mg/kg) increased the firing frequency compared to baseline
(p = 0.006) whereas the lowest dose of clozapine (0.01 mg/kg) showed no
effect (p = 0.312). A significant difference between the two doses of clozapine
on the mean firing frequency was observed (p = 0.003). Each bar represents
the mean firing frequency ±SEM (firing frequencies from individual neurons
represented by black squares). **p < 0.01 (two way repeated measures
ANOVA Bonferroni corrected).
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FIGURE 2 | Visualization of hM3Dq-mCherry expression in LC injected with PRSx8-driven AAV. (A–C) LC-NA neurons are visualized using primary anti-DBH
antibody (green) and expression of hM3Dq DREADD is visualized with the mCherry tag (red). (B) Aspecific hM3Dq expression (red) in DBH- non LC neurons.
(C) Only a low number of transduced neurons are observed in some animals. Scale bar 100 µm.
induction of DREADD expression, followed by LC unit recording
and subcutaneous clozapine injections to investigate the potential
to selectively modulate LC-NA neurons. This approach could
ultimately be used in the context of investigating the role
of the LC-NA pathway in regulating cortical excitability in
awake epileptic rats.
For chemogenetic modification we used the adeno-associated
viral vector (AAV2/7), previously used in the substantia nigra
(Van der Perren et al., 2011), to selectively express the excitatory
hM3Dq DREADD in LC neurons using the PRSx8 promoter.
Post-mortem analysis of hM3Dq presence in the brainstem
revealed low levels of expression in LC in combination with the
presence of aspecific expression in surrounding non-LC neurons.
The transduction efficiency of specific cells is defined by the
AAV serotype, promotor and injection site (Martin et al., 2002).
Our observed transduction levels were in contrast with high
specificity and expression levels of >95% in previous studies
using AAV2/9-PRSx8-hM3Dq-mCherry to transduce the LC
(Vazey and Aston-Jones, 2014). The serotype of the viral vector
may be one of the primary reasons for the poor expression
levels and aspecificity. The transduction efficiency of an AAV
is determined by AAV entry in the target cell (Lai et al., 2002)
which is controlled by the AAV capsid with its proteins on the
surface that determine the binding specificity and entry of the
virion to cells (Rabinowitz et al., 2002; Delbeke et al., 2017).
In contrast to other groups who use the AAV2/9 and achieve
high expression levels, in this study AAV2/7 was used which
means that the genome of serotype 2 is encapsulated in a viral
capsid formed by serotype 7 (Vazey and Aston-Jones, 2014;
Cope et al., 2019). Probably the presence of different surface
proteins presented on the capsid in comparison to AAV2/9
leads to lower binding affinity for the surface receptors on
LC-NA cells and possible affinity for non-LC cells, explaining
both low expression levels and aspecificity. Although previous
research has proven that AAV2/7 is as effective as AAV2/9
in transducing dopaminergic neurons in substantia nigra, this
might be different when targeting noradrenergic LC cells due
to their different receptors and co-receptors (Lai et al., 2002;
Van der Perren et al., 2011).
Next to the AAV serotype, expression specificity is also defined
by the promotor. The PRSx8 promoter is a synthetic DBH
promoter which consist of eight copies of a promoter sequence
from the cis-regulatory region of the DBH gene that binds
the Phox2a/b transcription factors. This promoter sequence has
proven to successfully drive gene expression in catecholaminergic
neurons expressing the Phox2a/b transcription factors (Hwang
et al., 2001) as described by other groups using AAV2/9-PRSx8
construct observing high expression levels (Vazey and Aston-
Jones, 2014). Because of these observations, it is less likely that
the observed aspecific expression in our study is due to promotor
characteristics. However, it is possible that due to the affinity
of the capsid for receptors present on non-LC cells, Phox2
transcription factors present in these non-catecholaminergic cells
(Bruinstroop et al., 2012) activate gene expression. Another
possible explanation might be the presence of transactivator
activity in the AAV inverted terminal repeats. Terminal repeats
(TR) contain sequences necessary for replication and packaging
of recombinant DNA and cannot be deleted. Haberman et al.
(2000) have shown that an AAV TR construct without promoter
can initiate gene expression, indicating its transcriptional and
promoter ability, resulting in a loss of tissue-specific expression
(Haberman et al., 2000). When the number of viral vector virions
Frontiers in Neuroscience | www.frontiersin.org 5 March 2020 | Volume 14 | Article 162
fnins-14-00162 March 4, 2020 Time: 16:55 # 6
Stevens et al. Chemogenetics to Investigate LC-NA Pathway
at the injection site is high [=high multiplicity of infection
(MOI)] the amount of TR mediated transcription can increase
or promotor leakage can occur, which means that the promotor
will be active in non-specific cells, resulting in detectable aspecific
expression (Bruinstroop et al., 2012).
Finally we cannot exclude the inadequate delivery of the
adeno-associated viral vector in the vicinity of LC as we
were not able to localize the exact injection site using
post-mortem immunohistochemical analysis (Sara and Hervé-
Minvielle, 1995). We use a validated technique to target LC
and observe expression in all injected animals supporting
the conclusion that the injection was performed correctly
(Rorabaugh et al., 2017; Cope et al., 2019).
The ultimate aim of the experiment was to determine whether
presumed subtherapeutic doses of clozapine could be used
to specifically activate DREADD expressing LC neurons in
anesthetized rats.
We found that LC unit recording is feasible following
manipulations to induce DREADD expression although the yield
is relatively low as we were only able to perform successful
electrophysiological recordings in 35% of the animals. This is
similar to other research groups targeting locus coeruleus with
success rates around 45% and is possibly due to the small size
and location of the nucleus in the pontine brainstem (Quinlan
et al., 2019). In the current experimental setting, we were not
able to draw conclusions on the feasibility to chemogenetically
increase LC neuronal activity with clozapine. Since only a limited
fraction of LC neurons showed expression of the DREADD
upon AAV injection, we could not claim that we recorded
from DREADD positive LC neurons in the DREADD group. In
fact, this study showed that 0.1 mg/kg clozapine increases the
firing rate of LC neurons even in the control group and thus
independent of DREADD expression. We can thus conclude that
0.1 mg/kg clozapine does significantly activate non-DREADD
neuroreceptors influencing the firing rate of LC neurons. This
dose is thus less suitable for future experiments to selectively
activate DREADD-expressing LC neurons (Gomez et al., 2017;
Mahler and Aston-Jones, 2018).
These DREADD-independent effects of low doses of clozapine
were not expected as previous studies using 0.1–10 mg/kg CNO
were without effects on LC firing frequency in control animals
(Vazey and Aston-Jones, 2014). These doses correspond or are
even higher than the doses of clozapine used in this study keeping
in mind that 10 mg/kg CNO ∼ 0.1 mg/kg clozapine described
by Gomez et al. (2017). A previous study in healthy animals
showed an increased firing frequency of LC and ventral tegmental
area neurons after intravenous administration of clozapine
(0.078 mg/kg – 10 mg/kg) (Nilsson et al., 2005; Schwieler et al.,
2008). Pretreatment with a selective antagonist at the glycine site
of the NMDA receptor inhibited the activation of LC neurons
after administration of the highest dose of clozapine but cannot
solely explain the increased firing frequency as administration
of a selective partial agonist of the glycine/NMDA receptor
did not increase the LC activity. However, it has been shown
that clozapine is able to increase extracellular glutamate levels
(Daly and Moghaddam, 1993). These findings suggest that a
combination of activating the glycine site of the NMDA receptor
and increased glutamatergic release, as a result of activation of
clozapine sensitive receptors located on glutamatergic afferents
to LC, might be responsible for activation of LC noradrenergic
neurons after administration of the highest dose of clozapine
(Nilsson et al., 2005). Local delivery of clozapine as performed by
Vazey et al. (Vazey and Aston-Jones, 2014), instead of systemic
administration (s.c.) could possibly rule out major effects of
activated glutamatergic afferents to LC, although activation of
presynaptic axons would still be possible. However, we chose in
our study to subcutaneously inject our animals, knowing that
clozapine has proven to cross the blood-brain-barrier easily and
to have a high affinity for DREADDs (Gomez et al., 2017). Due
to the absence of differences in effects on LC firing frequency
after administration of CNO locally or systemically (Vazey and
Aston-Jones, 2014) and with the future prospect of performing
experiments in awake animals, subcutaneous administration of
clozapine was preferred.
Next to activation of endogenous NMDA receptors, recent
studies suggest that low doses of clozapine, result in occupancy
of endogenous receptors in the brain and significant changes
in neurometabolite levels and effects on locomotion, anxiety
and cognitive flexibility (Bouret et al., 2003; Smith et al., 2016).
Clozapine has affinity for D2, M2, 5-HT1a, α1 and histamine
receptors present in LC which can also lead to excitation and
increased firing frequency (Egan and North, 1985; Szabo and
Blier, 2001; Korotkova et al., 2005; Bærentzen et al., 2019).
From our results and sequence of experimental steps, we
conclude that the use of AAV2/7 is less desirable to specifically
induce DREADD expression in LC neurons in comparison to
previously used approaches. A different AAV serotype such as the
AAV2/9 as discussed above leads to higher transduction levels
(Vazey and Aston-Jones, 2014; Fortress et al., 2015; Kane et al.,
2017; Rorabaugh et al., 2017; Cope et al., 2019; Zerbi et al., 2019).
Other groups have even used a different type of viral vector
(i.e., CAV) to induce the expression of opsins or engineered
ligand gated ion channels in the noradrenergic neurons resulting
in high expression patterns after direct injection in LC or
administration in LC projection areas (Li et al., 2016; Hirschberg
et al., 2017). These more successful approaches of induction
of genetic modifications in LC-NA neurons may be due to
higher affinity of the virion for the LC-NA surface receptors. An
alternative for increasing transduction efficiency and selectivity
is the use of a Cre-Lox system for hM3Dq expression in LC
(Witten et al., 2011). The group of Harley and Walling et al.
used a TH:Cre rat line to induce expression of an opsin in LC
by injecting a Cre-dependent AAV with the promoter and gene
of interest between loxP sites, assuring selective expression in
LC cells that contain Cre recombinase (Quinlan et al., 2019).
Because of these findings we believe that for further optimization
of the experimental approach studied in this work, transduction
efficiency studies with different viral vector serotypes is required
when targeting a new brain structure such as a brainstem nucleus,
even when a similar type of neurons i.e., noradrenergic neurons
are the primary content of the nucleus. An experimental setup
with higher transduction efficiency and selectivity is required in
combination with a technique to ensure that unit recording was
performed in transduced cells to validate the effect of clozapine
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as a possible selective DREADD ligand. We propose future viral
vector experiments with: (1) a different serotype (e.g., AAV2/9 or
CAV) to achieve more efficient transduction of LC-NA neurons;
(2) a lower titer to avoid aspecific expression due to possible
promoter leakage resulting from high MOI and/or (3) higher
injected volumes to cover more LC cells (Bruinstroop et al.,
2012; Vazey and Aston-Jones, 2014). To allow confirmation on
the transduction characteristics of the recorded LC neurons
in anesthetized rats juxtacellular labeling with neurobiotin can
be performed as proven by other groups performing LC unit
recording (Allers and Sharp, 2003; Hajós et al., 2007; Bangasser
et al., 2011; Dempsey et al., 2015).
Although this feasibility study demonstrated that our
approach is suboptimal to selectively modulate LC, we still
believe that chemogenetics, a technique which allows cell-
specific modulation is needed to further investigate the role
of this brainstem nucleus in brain excitability. A viral vector
approach with high transduction efficiency in combination with
LC-selective expression of DREADDs and a selective ligand
will enable us to study the effect of LC in the epileptic
brain and its role in attenuating seizures as observed during
VNS (Raedt et al., 2011). So far, experiments that used
electrical stimulation or infusion of chemicals to modulate
LC function gave ambiguous results concerning its role in
modulating hippocampal excitability. Electrical stimulation in LC
induced β-receptor-dependent long term depression (LTD) while
glutamate injection in LC induced long term potentiation (LTP)
in hippocampus (Walling, 2004; Hansen and Manahan-Vaughan,
2015). Some LC activation studies show increased hippocampal
responses to afferent input (Haas and Rose, 1987; Dahl and
Sarvey, 1990; Sara and Bergis, 1991; Knight and Harley, 2006;
Reid and Harley, 2010; Edison and Harley, 2012) while others
demonstrate reduced gamma power reflecting decreased activity
of local hippocampal neurons (Brown et al., 2005; Walling et al.,
2011). These contradictory results might be the result of the
small size and deep location of the LC, making the risk of off-
target effects by non-selective electrical and chemical stimulation
techniques likely.
These findings emphasize that further research using
chemogenetics is necessary in the field of LC research,
allowing cell-specific modulation and defining its function in
brain excitability and confirming its role in the mechanism
of action of VNS.
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